Aura Biosciences expanded its board from six to seven members on July 3, 2026, appointing Jeremy Bender as a new Class II director effective July 7. Bender also joined the Compensation and Nominating/Corporate Governance Committees. As an independent director, he received an initial stock option grant for 60,000 shares and 30,000 restricted stock units, vesting over three years. The company also disclosed its updated non-employee director compensation policy, with higher cash retainers and increased equity awards compared to the previous version. Bender is eligible for the same cash compensation as other non-employee directors under this policy.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding AURA BIOSCIENCES INC (AURA)?

Major stakeholders currently include Matrix Capital Management Company, LP ($46.3M), Frazier Life Sciences Management, L.P. ($34.1M), Adage Capital Partners Gp, L.l.c. ($32.7M). Based on the latest 13F filings, there are a total of 126 tracked investment funds and institutions maintaining positions in AURA.

What is the overall institutional sentiment toward AURA recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $68.8M, driven by 58 managers accumulating shares while 55 reduced their exposure.

Which institutions have been selling or reducing their AURA positions?

In the latest period, 42 funds trimmed their holdings, and 13 managers completely exited their positions. The aggregate reported sell value was $36.3M.

Are there any notable investors adding AURA to their portfolios?

Yes, buying activity remains notable. 19 institutions opened new positions in {ticker}, and 39 existing holders added to their shares. The total reported buy value for the quarter amounted to $73.1M.